Global Celecoxib Market Size, Share, Trends and Forecast 2022-2030

Description

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.

Industry Insights

Due to the COVID-19 pandemic, the global Celecoxib market size is estimated to be worth US$ 1271.3 million in 2021 and is forecast to a readjusted size of US$ 2250.6 million by 2028 with a CAGR of 8.4% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Celecoxib market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Celecoxib landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Data show that more than 400 million people worldwide are currently affected by joint diseases.

The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.

The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.

At present, the burden of chronic diseases will increase by 40% due to the aging of the population.

As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.

Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.

At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.

At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.

It accounted for 63.39% of the global market in 2019.

As of 2019, China relies entirely on Pfizer for celecoxib imports.

Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.

This report focuses on Celecoxib volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Celecoxib market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and China, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Celecoxib market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

50mg

100mg

200mg

400mg

Segment by Application

Rheumatoid arthritis

osteoarthritis

Acute pain

Musculoskeletal pain

Other diseases

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Pfizer Inc

Teva

Mylan

Apotex

Lupin

Hengrui Medicine

TABLE OF CONTENT

1 Celecoxib Market Overview
1.1 Product Overview and Scope of Celecoxib

1.2 Celecoxib Segment by Type

1.2.1 Global Celecoxib Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 50mg

1.2.3 100mg

1.2.4 200mg

1.2.5 400mg

1.3 Celecoxib Segment by Application

1.3.1 Global Celecoxib Sales Comparison by Application: (2022-2028)

1.3.2 Rheumatoid arthritis

1.3.3 osteoarthritis

1.3.4 Acute pain

1.3.5 Musculoskeletal pain

1.3.6 Other diseases

1.4 Global Celecoxib Market Size Estimates and Forecasts

1.4.1 Global Celecoxib Revenue 2017-2028

1.4.2 Global Celecoxib Sales 2017-2028

1.4.3 Celecoxib Market Size by Region: 2017 Versus 2021 Versus 2028

2 Celecoxib Market Competition by Manufacturers

2.1 Global Celecoxib Sales Market Share by Manufacturers (2017-2022)

2.2 Global Celecoxib Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Celecoxib Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Celecoxib Manufacturing Sites, Area Served, Product Type

2.5 Celecoxib Market Competitive Situation and Trends

2.5.1 Celecoxib Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Celecoxib Players Market Share by Revenue

2.5.3 Global Celecoxib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Celecoxib Retrospective Market Scenario by Region

3.1 Global Celecoxib Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Celecoxib Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Celecoxib Market Facts & Figures by Country

3.3.1 North America Celecoxib Sales by Country

3.3.2 North America Celecoxib Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe Celecoxib Market Facts & Figures by Country

3.4.1 Europe Celecoxib Sales by Country

3.4.2 Europe Celecoxib Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Celecoxib Market Facts & Figures by Region

3.5.1 Asia Pacific Celecoxib Sales by Region

3.5.2 Asia Pacific Celecoxib Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America Celecoxib Market Facts & Figures by Country

3.6.1 Latin America Celecoxib Sales by Country

3.6.2 Latin America Celecoxib Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Celecoxib Market Facts & Figures by Country

3.7.1 Middle East and Africa Celecoxib Sales by Country

3.7.2 Middle East and Africa Celecoxib Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Celecoxib Historic Market Analysis by Type

4.1 Global Celecoxib Sales Market Share by Type (2017-2022)

4.2 Global Celecoxib Revenue Market Share by Type (2017-2022)

4.3 Global Celecoxib Price by Type (2017-2022)

5 Global Celecoxib Historic Market Analysis by Application

5.1 Global Celecoxib Sales Market Share by Application (2017-2022)

5.2 Global Celecoxib Revenue Market Share by Application (2017-2022)

5.3 Global Celecoxib Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Pfizer Inc

6.1.1 Pfizer Inc Corporation Information

6.1.2 Pfizer Inc Description and Business Overview

6.1.3 Pfizer Inc Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Pfizer Inc Celecoxib Product Portfolio

6.1.5 Pfizer Inc Recent Developments/Updates

6.2 Teva

6.2.1 Teva Corporation Information

6.2.2 Teva Description and Business Overview

6.2.3 Teva Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Teva Celecoxib Product Portfolio

6.2.5 Teva Recent Developments/Updates

6.3 Mylan

6.3.1 Mylan Corporation Information

6.3.2 Mylan Description and Business Overview

6.3.3 Mylan Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Mylan Celecoxib Product Portfolio

6.3.5 Mylan Recent Developments/Updates

6.4 Apotex

6.4.1 Apotex Corporation Information

6.4.2 Apotex Description and Business Overview

6.4.3 Apotex Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Apotex Celecoxib Product Portfolio

6.4.5 Apotex Recent Developments/Updates

6.5 Lupin

6.5.1 Lupin Corporation Information

6.5.2 Lupin Description and Business Overview

6.5.3 Lupin Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Lupin Celecoxib Product Portfolio

6.5.5 Lupin Recent Developments/Updates

6.6 Hengrui Medicine

6.6.1 Hengrui Medicine Corporation Information

6.6.2 Hengrui Medicine Description and Business Overview

6.6.3 Hengrui Medicine Celecoxib Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Hengrui Medicine Celecoxib Product Portfolio

6.6.5 Hengrui Medicine Recent Developments/Updates

7 Celecoxib Manufacturing Cost Analysis

7.1 Celecoxib Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Celecoxib

7.4 Celecoxib Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Celecoxib Distributors List

8.3 Celecoxib Customers

9 Celecoxib Market Dynamics

9.1 Celecoxib Industry Trends

9.2 Celecoxib Market Drivers

9.3 Celecoxib Market Challenges

9.4 Celecoxib Market Restraints

10 Global Market Forecast

10.1 Celecoxib Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Celecoxib by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Celecoxib by Type (2023-2028)

10.2 Celecoxib Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Celecoxib by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Celecoxib by Application (2023-2028)

10.3 Celecoxib Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Celecoxib by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Celecoxib by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample